During the corresponding time, Amneal Pharmaceuticals Inc recorded a revenue increase by 9.93 % year on year, sequentially revenue grew by 10.26 %. While revenue at the Amneal Pharmaceuticals Inc 's corporate clients
Amneal Pharmaceuticals Inc's Comment on Sales, Marketing and Customers
The company primarily serves the U.S. hospital market with institutional injectable products and has a growing portfolio in this segment. It also operates in international markets. Its Affordable Medicines segment focuses on generic pharmaceuticals, including first-to-file (FTF) and first-to-market (FTM) products. The company has expanded its respiratory platform with FDA approvals for beclomethasone dipropionate HFA inhalation aerosol (generic QVAR) and albuterol sulfate inhalation aerosol (generic ProAir HFA), enhancing its presence in complex inhalation and drug-delivery technologies. Additionally, it commercializes oncology biosimilars in the U.S., including ALYMSYS (biosimilar referencing Avastin), Releuko (biosimilar referencing Neupogen), and Flynetra (biosimilar referencing Neulasta). The FDA has accepted biologics license applications (BLAs) for two denosumab biosimilars referencing Prolia and XGEVA.
Amneal Pharmaceuticals Releases 2023 Environmental, Social, and Governance Report: A Commitment to Sustainable Business Practices and Social ResponsibilityAmneal Pharmaceuticals, a leading global pharmaceutical company, has recently unveiled its highly anticipated fourth Environmental, Social, and Governance (ESG) Report for the year 2023. This comprehensive report showcases the significant progress made by Amneal in relation to its core ESG priorities and highlights the company s steadfast commitment to embedding sustainability throughout its entire business operations.The report serves as a testimony to Amneal s ongoing efforts in addressing environmental issues, promoting social responsibility, and ensuri...
Amneal Pharmaceuticals, Inc. has recently entered into an exclusive licensing agreement with Zambon Biotech SA to bring a novel treatment for Parkinson s disease (PD) to the European Union, United Kingdom, and Switzerland. The licensing agreement covers the distribution and commercialization of IPX203, an oral formulation of carbidopa/levodopa (CD/LD) extended-release capsules.IPX203 offers a promising solution for individuals suffering from PD, a neurodegenerative disorder that affects millions of people worldwide. Parkinson s is characterized by the progressive deterioration of motor functions, leading to physical and cognitive impairments. CD/LD is the gold standard therapy used to manage the symptoms of ...
Amneal Pharmaceuticals Makes Historic Move to Nasdaq, Driving Growth and Innovation in Biotech Industry Bridgewater, New Jersey - In a groundbreaking decision, Amneal Pharmaceuticals, Inc. (Amneal) (NYSE: AMRX) announced its plans to transfer its stock exchange listing from the New York Stock Exchange (NYSE) to the Nasdaq Stock Market (Nasdaq). The move is expected to take place on December 27, 2023, and Amneal will retain its current trading symbol, AMRX. This strategic shift to Nasdaq will position Amneal as a key player in the Nasdaq Composite Index and Nasdaq Biotechnology Index, fueling its growth and enabling the company to thrive within the dynamic world of biopharmaceuticals. Amneal s decisio...
Amneal Pharmaceuticals Secures U.S. Licensing Agreement with BIAL for ONGENTYS (opicapone) Bridgewater, N.J. and Porto, Portugal- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) and BIAL - Portela and Ca., S.A. (BIAL) have recently announced a significant licensing agreement that grants Amneal exclusive rights to market and distribute ONGENTYS (opicapone) in the United States. This agreement is set to take effect on December 18, 2023, with Amneal anticipating the commencement of ONGENTYS distribution in early 2024. ONGENTYS, BIAL s revolutionary once-daily, peripherally-acting, highly-selective catechol-O-methyltransferase (COMT) inhibitor, holds promising potential in the treatment of neurological disorders.<...
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) has recently made an exciting addition to its portfolio by acquiring the rights to Icosapent ethyl acid soft gel capsules. This innovative product, which references VASCEPA, has been in-licensed from Strides Pharma Science Limited, a renowned global pharmaceutical manufacturer. Amneal is set to commence commercialization of the capsules in the fourth quarter of 2023. Icosapent ethyl acid soft gel capsules are available in two strengths, 0.5g and 1g, and serve as an ethyl ester of eicosape. This unique composition presents new opportunities for Amneal to cater to a wider range of patients, potentially contributing to the company s growth and market presence.<...
Amneal Pharmaceuticals Inc’s Comment on Sales, Marketing and Customers
The company primarily serves the U.S. hospital market with institutional injectable products and has a growing portfolio in this segment. It also operates in international markets. Its Affordable Medicines segment focuses on generic pharmaceuticals, including first-to-file (FTF) and first-to-market (FTM) products. The company has expanded its respiratory platform with FDA approvals for beclomethasone dipropionate HFA inhalation aerosol (generic QVAR) and albuterol sulfate inhalation aerosol (generic ProAir HFA), enhancing its presence in complex inhalation and drug-delivery technologies. Additionally, it commercializes oncology biosimilars in the U.S., including ALYMSYS (biosimilar referencing Avastin), Releuko (biosimilar referencing Neupogen), and Flynetra (biosimilar referencing Neulasta). The FDA has accepted biologics license applications (BLAs) for two denosumab biosimilars referencing Prolia and XGEVA.
Sources:
Amneal Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Amneal Pharmaceuticals Inc’s corporate clients.
For your research, we’ve provided 9 tables on Amneal Pharmaceuticals Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
114.69 %